Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine

• Published in: Clinical cancer research Vol. 29; no. 2; pp. 389 - 400
• Main Authors: Asleh, Karama, Lluch, Ana, Goytain, Angela, Barrios, Carlos, Wang, Xue Q, Torrecillas, Laura, Gao, Dongxia, Ruiz-Borrego, Manuel, Leung, Samuel, Bines, José, Guerrero-Zotano, Ángel, García-Sáenz, Jose Ángel, Cejalvo, Juan Miguel, Herranz, Jesus, Torres, Roberto, Haba-Rodriguez, Juan de la, Ayala, Francisco, Gómez, Henry, Rojo, Federico, Nielsen, Torsten O, Martin, Miguel
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 17.01.2023
• Subjects: Adjuvants, Immunologic - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Breast Neoplasms - drug therapy; Capecitabine - therapeutic use; Chemotherapy, Adjuvant; Endothelial Cells - pathology; Female; Humans; Precision Medicine and Imaging; Triple Negative Breast Neoplasms - drug therapy; Triple Negative Breast Neoplasms - genetics; Triple Negative Breast Neoplasms - pathology

Predictive biomarkers for capecitabine benefit in triple-negative breast cancer (TNBC) have been recently proposed using samples from phase III clinical trials, including non-basal phenotype and biomarkers related to angiogenesis, stroma, and capecitabine activation genes. We aimed to validate these...